According to Regeneron, the drug is a bispecific antibody that binds to B-cell maturation antigen (BCMA) on cancerous plasma cells and CD3 on T cells, directing the immune system to attack and destroy ...

Cancer-hunting antibodies coupled with a natural compound found in soil microbes proved a powerful combination against an aggressive type of blood cancer, according to a new study from scientists at ...

Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood ...

This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.

Worldwide, at least seven people have been "cured" of HIV—or at least have had long-term sustained remission. This means that ...

Antibody therapies constitute a vast global market: currently valued at over $250 billion, the market for antibodies is ...

A revolutionary new type of "Trojan horse" cancer therapy, now being deployed under the National Health Service in England, ...

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- Several experts are seeing that ...

As startups navigate the growing biotech sector in Wales, here are five biotech companies that are making waves in 2025.

Will the U.S. government adopt price controls on prescription drugs? If so, what would they look like? Seeking Alpha analysts ...

A once-a-day pill that could completely revolutionise the treatment of Alzheimer’s disease has reached a significant ...

Antibody-drug conjugates (ADCs) represent a mechanistically defined class of targeted therapeutics that combine monoclonal antibodies with cytotoxic payloads to achieve selective delivery to ...